Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Discovery & Development Drug Discovery

Bacteria to the Future

“Antimicrobial resistance is one of the greatest threats to global public health,” says Robert Baldock, Senior Lecturer in Biomedical Sciences at the University of Portsmouth, UK. “Although microorganisms gradually become resistant to current therapies, this challenge has been compounded by the ‘discovery void’ of new antibiotics to replace current drugs.” Baldock is working to understand the mechanistic insights behind human disease to design more targeted, repurposable drugs – and a key part of his research is antibiotic activity.

Since 2017, Baldock’s team has worked to identify compounds with antibacterial properties. Efforts to reduce inappropriate antimicrobial use have bought time, but the world still needs new – or repurposed – antimicrobial compounds. A joint effort from Baldock’s team and Naresuan and Pibulsongkram Rajabhat Universities in Thailand revealed hydroquinine’s antibacterial effects against several clinically important bacteria, including Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and a multidrug-resistant strain of Pseudomonas aeruginosa (1).

Next, the researchers hope to uncover the drug’s mechanism of action, as well as the reasons behind a tendency to induce a specific RND-type efflux pump alongside a concomitant bacterial infection (as seen in established antimalarial drugs containing hydroquinine).

Naturally occurring substances such as tree sap, where hydroquinine is sometimes found, can be rich sources of antibiotic activity. Baldock says, “We now need to investigate the activity of the compound against a wider array of bacterial strains to understand which bacteria are susceptible to the activity of this drug. Uncovering the molecular target of hydroquinine will be important in understanding why bacteria are either susceptible or resistant to this compound.”

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. R Baldock et al., Trop Med Infect Dis, 7, 156 (2022). DOI: 10.3390/tropicalmed7080156.
About the Author
Rob Coker

Deputy Editor of The Medicine Maker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and TMM.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register